Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

110.00
+1.080.99%
Post-market: 110.000.00000.00%19:30 EDT
Volume:523.14K
Turnover:57.65M
Market Cap:7.57B
PE:-35.29
High:112.59
Open:109.38
Low:106.58
Close:108.92
52wk High:122.20
52wk Low:74.50
Shares:68.85M
Float Shares:65.39M
Volume Ratio:1.08
T/O Rate:0.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1172
EPS(LYR):-3.1100
ROE:-117.04%
ROA:-30.96%
PB:73.54
PE(LYR):-35.37

Loading ...

Rhythm Pharmaceuticals (RYTM) Faces A Big Undervaluation Call, Is The Upside Already Priced In?

Simply Wall St.
·
Jul 27

Wells Fargo Releases a Buy Rating on Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Jul 16

Rhythm’s Setmelanotide Extension Study: What Long-Term Data Could Mean for RYTM

TIPRANKS
·
Jul 16

Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Jul 15

Does NEJM-Validated TRANSCEND Data on Setmelanotide Reshape the Bull Case for Rhythm Pharmaceuticals (RYTM)?

Simply Wall St.
·
Jul 13

Rhythm Pharmaceuticals Announces the New England Journal of Medicine Publication of Phase 3 Transcend Trial Results in Acquired Hypothalamic Obesity

THOMSON REUTERS
·
Jul 09

Medicare Coverage Could Put These Obesity Drug Stocks In Focus

Simply Wall St.
·
Jun 30

Rhythm Pharmaceuticals on Track for Highest Close Since January

Dow Jones
·
Jun 25

Rhythm Pharma Director Lynn A. Tetrault Disposes of Common Shares Worth $3.71 Million

Reuters
·
Jun 25

Rhythm Pharmaceuticals (RYTM) Stock Could Be 30.6% Undervalued on Its Growth Narrative

Simply Wall St.
·
Jun 22

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Jun 17

Rhythm Pharmaceuticals Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Jun 17

Rhythm Pharmaceuticals Inc : Canaccord Genuity Raises Target Price to $151 From $143

THOMSON REUTERS
·
Jun 16

BRIEF-Rhythm Pharmaceuticals Announces Multiple New Data Presentations From Mc4r Agonists

Reuters
·
Jun 16

Rhythm Pharma says setmelanotide cuts BMI 18.9% at 2.5 years in hypothalamic obesity study

Reuters
·
Jun 16

Rhythm Pharmaceuticals Announces Multiple New Data Presentations From Mc4r Agonists in Acquired Hypothalamic Obesity (Ho), Bardet-Biedl Syndrome (Bbs) and Prader-Willi Syndrome (Pws) at Endo 2026

THOMSON REUTERS
·
Jun 16

Rhythm Pharmaceuticals (RYTM) Receives a Buy from Jefferies

TIPRANKS
·
Jun 15

Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Rhythm Pharmaceuticals (RYTM) and Belite Bio, Inc. ADR (BLTE)

TIPRANKS
·
Jun 15

Rhythm announces preliminary data from Phase 2 trial of setmelanotide

TIPRANKS
·
Jun 15

Rhythm Pharmaceuticals (RYTM) Stock After Positive Phase 2 PWS Data What Does The Valuation Suggest

Simply Wall St.
·
Jun 15